Number 3: The FDA approved the first 2 biosimilars referencing Eylea (aflibercept)—Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)—for the treatment of ophthalmic conditions.

In the IQVIA Use of Medicines in the US 2024 report, biosimilar were found to be large contributors to lower drug costs and ...

The FDA announced that it approved the first 2 biosimilars referencing Eylea (aflibercept) for the treatment of ophthalmic ...

Posters from Digestive Disease Week (DDW) looking at the ongoing LIBERTY-CD trial looking Zymfentra, a subcutaneous ...

The discussion highlighted key emerging trends from the Festival of Biologics conference and the annual Cardinal Health ...

Sarfaraz K. Niazi, PhD, congratulates the FDA on approving the fiftieth biosimilar, noting that there's more work to be done ...

Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, ...

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, predicting ...

At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost ...

A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, ...